Search Results for:
-
'JAK'ing Up Myelofibrosis; Sanofi's Phase III Data Solid
As sales of Incyte Corp.'s approved JAK inhibitor Jakafi (ruxolitinib) begin to pick up steam, a competing myelofibrosis candidate from Sanofi SA moved a step closer to market. The Paris-based big pharma, which gained rights to JAK drug SAR302503 in its 2010 buyout of TargeGen Inc., reported solid top-line data from the Phase III study dubbed JAKARTA, showing that both dose groups of the drug hit the primary endpoint of reducing spleen volume. The study was conducted under a special protocol -
Oncos Targets Solid Tumors With Oncolytic Virus Approach
Taking an inventive route to drug development, Oncos Therapeutics Ltd. has its roots in a type of compassionate use program that was started in 2007 at the international comprehensive cancer center, Docrates, in Helsinki, Finland. The Advanced Therapy Access Program for experimental treatments with the company's oncolytic viruses was made possible through European Union (EU) regulation EC/1394/2007, designed to improve safe access by patients across the EU to gene therapy, somatic cell therapy -
Pharma: Other News To Note
Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs. Mylan Inc., of Pittsburgh, said its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals received final approval from -
Appointments and Advancements
Aeterna Zentaris Inc., of Quebec City, added Marcel Aubut, David A. Dodd, José P. Dorais, Carolyn Egbert, Juergen Ernst, Pierre Lapalme and Gérald Limoges to its board. AltheRx Pharmaceuticals Inc., of Exton, Pa., named Jim Bennethum CEO, appointed Charles E. Becker board chairman and named Jeffrey O'Donnell and Anthony Zook to its new board of directors. BG Medicine Inc., of Waltham, Mass., appointed Paul Sohmer president and CEO. Biota Pharmaceuticals Inc., of Rockville, Md., added Anne -
Pharma: Clinic Roundup
UCB SA, of Brussels, Belgium, said data from a double-blind, placebo-controlled study found that Neupro (rotigotine transdermal system) reduced total nocturnal systolic blood pressure (NSBP) elevations associated with periodic limb movements during sleep (PLMS) and total PLMS in patients with idiopathic moderate to severe restless legs syndrome (RLS)/Willis-Ekbom disease. The data were presented at the annual meeting of the American Society of Hypertension. Results showed that rotigotine -
Clinic Roundup
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of human adipose-derived mesenchymal progenitor cells therapy for knee osteoarthritis. No severe adverse effects have been reported so far. Cytos Biotechnology AG, of Zurich, Switzerland, and Singapore's Agency for Science, Technology and Research (A*STAR) said the first healthy volunteer has been -
A&G Pharmaceutical Inc.
-
A.P. Pharma Inc.
-
A/F Protein Inc.
-
Aarden Pharmaceuticals Inc.
-
Aastrom Biosciences Inc.
-
AB Enzymes GmbH
-
Abbott Diabetes Care
-
Abbott
-
AbbVie
-
Abengoa SA
-
AbGenomics Corp.
-
Ablitech Inc.
-
Ablynx NV
-
Abraxis BioScience Inc.
Category
Current Filters
- xNOT RNAi Report
Categories
- x BioWorld Today (38918)
- x BioWorld International (7391)
- x BioWorld Insight (6613)
- x Bioscan (2265)
- x Bio Perspectives (1205)
- x BioWorld Phase III Report (629)
- x State of the Industry Report (609)
- x BioWorld Genomics Review (496)
- x Executive Compensation Report (255)
- x Top 25 Drug Report (176)
- x BioWorld Snapshots (90)
- x Biotech Innovations (76)
- x Market-Leading Biotech Drugs (29)
- x Recorded (17)
- x MDD (7)
- x Featured (7)
- x BioWorld Executive Compensation Report 2013 (1)
- x Upcoming (1)
- x BioWorld Today (1)
- x Medical Advances (1)